INS-2301

Insulin Without Needles

Needle phobia is the Achilles heel of Insulin compliance. Not just for children, many adults also hate piercing their skin with an injection. InsuLife is on a mission to change this with INS-2301, an investigational medicinal skin-applied insulin.
The Future of Insulin Delivery
INS-2301 aims to be the first skin-applied Insulin. Applied directly onto the skin, INS-2301 eliminates the use of needles. The target of this breakthrough product:
  • Eliminates multiple injections per day
  • Potential for better patient compliance
  • Utilizes recombinant human insulin, a “commodity” drug product enabling cost competitiveness

Transdermal Delivery

The ability to transport a drug molecule through the skin is controlled by the dipole moment in a solution of the drug.

Substances which go through the skin readily have approximately the same dipole moment, and Hypospray Pharma has developed solutions that enable managing for the dipole moment so that the drug can be absorbed through the skin.

The solvents used are ethanol andpropylene carbonate, a total of 95%. In addition, a proprietary mixture of several naturally occurring substances are added in order to impact the dipole moment of the solution.

How does the Insulin Molecule Enter Through the Skin?

During the InsuLife update seminar held on December 8th, 2022, an audience member raised the question: since the insulin molecule is so big, how does your technology manage to enter through the skin and not have to use a needle? Watch our Chief Science Officer, Dr. Chandan Alam, explain how it works.
Subscribe for InsuLife News Updates
Sign up to receive the latest InsuLife news, updates and investing information delivered right to your inbox.
Newsletter Form (#1)
InsuLife is a Norwegian company aiming at bringing the unparalleled developmental INS-2301 skin-applied insulin to market.
Learn More
© Copyright 2024 - InsuLife AS, All Rights Reserved
cross